Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01402687 · ClinicalTrials.gov registry record
SNP-Based Prediction of Oral Mucositis Risk in Patients Receiving Hematopoietic Stem Cell Transplants (HSCT)
A clinical trial, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- 181
- Enrollment target
NCT01402687: Completed study, sponsored by Dana-Farber Cancer Institute.
NCT01402687 is a clinical trial that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 181 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01402687 has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- 181 participants
- Enrollment target
Study Summary
The goal of this study is to gain new knowledge about genetic risk factors thta may affect the development of mucositis, the chemotherapy-induced sores in the mouth and esophagus following HSCT. The study seeks to understand if different forms of genes result in an increased risk of sores in the mouth and esophagus.
Primary Outcome
Develop and validate a clinically applicable SNP-based screening platform that will define mucositis risk among patients undergoing conditioning regimens for HSCT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 181 participants |
| Start Date | 2010-10 |
| Est. Completion | 2013-06 |
What the finished NCT01402687 record still lists
NCT01402687 is an observational study that tracks outcomes without assigning an intervention. The registered 181 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT01402687 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01402687 about?
NCT01402687 is a clinical study titled "SNP-Based Prediction of Oral Mucositis Risk in Patients Receiving Hematopoietic Stem Cell Transplants (HSCT)". The goal of this study is to gain new knowledge about genetic risk factors thta may affect the development of mucositis, the chemotherapy-induced sores in the mouth and esophagus following HSCT. The study seeks to understand if different forms of genes result in an increased risk of sores in the mou...
What is the current status of trial NCT01402687?
This trial is currently completed. The enrollment target is 181 participants. The study started on 2010-10. Estimated completion is 2013-06.
Who is sponsoring clinical trial NCT01402687?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04578392 · 181 participants · NA
MeSenteric SpAring Versus High Ligation Ileocolic Resection for the Prevention of REcurrent Crohn's DiseaSe (SPARES)
- NCT05597891 · 181 participants · NA
Endovascular Engineering ENGULF Study
- NCT03897998 · 182 participants · Phase 2
Neural Correlates of Hypoalgesia Driven by Observation
- NCT04300556 · 182 participants · Phase 1
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia